Bendell, J. C., Hochster, H., Hart, L. L., Firdaus, I., Mace, J. R., McFarlane, J. J., . . . Cohn, A. L. (2017). A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. Oncologist.
শিকাগো স্টাইলে সাইটেশনBendell, Johanna C., et al. "A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab With or Without the MET Inhibitor Onartuzumab in Patients With Metastatic Colorectal Cancer." Oncologist 2017.
এমএলএ সাইটেশনBendell, Johanna C., et al. "A Phase II Randomized Trial (GO27827) of First‐Line FOLFOX Plus Bevacizumab With or Without the MET Inhibitor Onartuzumab in Patients With Metastatic Colorectal Cancer." Oncologist 2017.